Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Julie A. Ellerhorst"'
Autor:
Elizabeth A. Grimm, Alexander J. Lazar, Genevieve Lyons, Chandrani Chattopadhyay, Julie A. Ellerhorst, Mariana Petaccia de Macedo, Wei Lien Wang, Junna Oba, Bita Esmaeli, Denái R. Milton
Publikováno v:
Melanoma Research. 27:126-133
This exploratory study was carried out to determine the expression levels of hepatocyte growth factor (HGF), insulin-like growth factor 1, thyroid-stimulating hormone (TSH), and leptin in serum and tumor samples from patients with uveal melanoma and
Autor:
Julie A. Ellerhorst, Junna Oba, Cynthia M. Wyatt, Marcella M. Johnson, Elizabeth A. Grimm, Wei Wei, Jeffrey E. Gershenwald
Publikováno v:
Medicine
Supplemental Digital Content is available in the text
The metabolic hormone leptin has been implicated in the pathogenesis of various malignancies and may contribute to the high rate of cancer in obese individuals. We reported that leptin and it
The metabolic hormone leptin has been implicated in the pathogenesis of various malignancies and may contribute to the high rate of cancer in obese individuals. We reported that leptin and it
Autor:
Carla L. Warneke, Marcella M. Johnson, Li E. Wang, Qingyi Wei, Suhendan Ekmekcioglu, Victor G. Prieto, Victoria R. Greene, Jeffrey E. Gershenwald, Elizabeth A. Grimm, Julie A. Ellerhorst, C. P. Cooke
Publikováno v:
Clinical Cancer Research. 17:229-235
Purpose: NRAS and BRAF mutations are common in cutaneous melanomas, although rarely detected mutually in the same tumor. Distinct clinical correlates of these mutations have not been described, despite in vitro data suggesting enhanced oncogenic effe
Publikováno v:
Journal of Investigative Dermatology. 129(6):1483-1488
A lack of consensus exists with regards to the relative rates of NRAS and BRAF mutations in the radial (RGP) and vertical (VGP) growth phases of individual melanoma tumors. This study was conducted to test the hypothesis that mutations are acquired w
Autor:
Elizabeth A. Grimm, Cindy S. Hwang, Abdul H. Diwan, Gregory Lizée, Patrick Hwu, Omar Eton, Victor G. Prieto, Sandra A. Kinney, Kevin B. Kim, Ping Liu, Julie A. Ellerhorst, Suhendan Ekmekcioglu
Publikováno v:
Melanoma Research. 18:241-245
Response to treatment with imatinib mesylate has been associated in preclinical models with the inhibition of two signaling pathways that promote cellular survival - the phosphatidylinositol 3-kinase/AKT pathway and the mitogen-activated protein kina
Autor:
C. P. Cooke, Shyam M Dang, A. Hafeez Diwan, Marilyn K. Johnson, Aresu Sendi-Naderi, Julie A. Ellerhorst
Publikováno v:
Endocrine-Related Cancer. 13:1269-1277
We have reported a high prevalence of hypothyroidism in the cutaneous melanoma population, suggesting that the pathologic hormonal environment of hypothyroidism promotes melanoma growth. The objective of this study was to test the hypothesis that TSH
Autor:
Julie A. Ellerhorst, Suhendan Ekmekcioglu, Elizabeth A. Grimm, Marcella M. Johnson, Victor G. Prieto, Lyle D. Broemeling
Publikováno v:
International Journal of Cancer. 119:861-866
Inducible nitric oxide synthase (iNOS) produces nitric oxide, which has growth promoting activity in melanoma. A preliminary study of tumors from patients with Stage III melanoma who had received neo-adjuvant therapy revealed an association of tumor
Autor:
Abner M. Mhashilkar, R. Bryan Sutton, Nancy Poindexter, Kelly K. Hunt, Jack A. Roth, Elizabeth A. Grimm, Suhendan Ekmekcioglu, Heng Yin Yang, Aysegul A. Sahin, Wolfgang W. Leitner, Kerry L. Fuson, John B. Mumm, Sunil Chada, Julie A. Ellerhorst, Rajagopal Ramesh
Publikováno v:
International Immunopharmacology. 4:649-667
The melanoma differentiation associated gene-7 (mda-7) cDNA was isolated by virtue of being induced during melanoma differentiation. Initial gene transfer studies convincingly demonstrated potent antitumor effects of mda-7. Further studies showed tha
Autor:
Theresa Smith, Omar Eton, Julie A. Ellerhorst, Agop Y. Bedikian, Nicholas Papadopoulos, Carl Plager
Publikováno v:
Melanoma Research. :63-66
In four clinical trials in mostly chemotherapy-naive patients with metastatic melanoma, paclitaxel was found to be effective with a response rate of 16%. In vitro studies have shown that following exposure of cancer cells to paclitaxel for 1 h, sensi
Autor:
Harald Fischer, Julie A. Ellerhorst, William H. Hildebrand, Marcelo Fernandez-Vina, Nancy Poindexter, Sherie Hodges, Joshua W. Cavett, Elizabeth A. Grimm
Publikováno v:
Journal of Urology. 169:2084-2088
Durable responses to cytokine therapy occur in a small subset of patients with renal cell carcinoma. We determined if a common HLA genotype existed among these patients which might be associated with response and survival.The study population consist